Research Article

**Bupleuri Radix Prevents the Recurrences of Resected Colonic Polyps by Affecting Angiogenin-2-Induced Protein Kinase B/Akt Signaling**

Qiang Gao,1 Guihong Yu,2 Minghui Yu,3 and Xinping Wang4

1Department of Spleen and Stomach Disease, Yantai Hospital of Traditional Chinese Medicine, Yantai 264002, China
2Department of Integrated TCM & Western Medicine, Yantai Qishan Hospital, Yantai 264000, China
3Department of Clinical Laboratory, Yantai Wanhua Hospital, Yantai 260000, China
4Department of Clinical Laboratory, Yantai Hospital of Traditional Chinese Medicine, Yantai 264002, China

Correspondence should be addressed to Xinping Wang; wangxinping19@126.com

Received 15 June 2020; Revised 2 October 2020; Accepted 14 October 2020; Published 28 October 2020

Academic Editor: Dali Zheng

Copyright © 2020 Qiang Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Aim.** We aimed to explore the effects of Bupleuri Radix (BR) on the recurrence of resected colonic polyp (CP) by measuring angiogenin-2-induced protein kinase B (Ang PKB)/Akt signaling. **Method.** The main ingredients of BR were extracted by using ethanol and measured by HPLC. One hundred twenty patients with CP >10 mm who underwent resected surgery were randomly allocated to an aspirin (AG) or a BR medicine (BG) group. The allocation ratio was 1:1 and the intervention duration was one year. The recurrence rate of resected CP was investigated and the plasma levels of Ang PKB/Akt and inflammatory cytokines were measured using ELISA kits. After one-year surgery, side effects were recorded. The relationship between the serum levels of the main compounds of BR and plasma levels of Ang PKB/Akt was analyzed. **Results.** The main ingredients of CP are paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2. Recurrence of resected CP was found in 17 patients from the AG group and eight patients from the BG group after one-year follow-up (p < 0.05). The levels of angiogenin-2 II and PKB/Akt in the AG group were higher than those in the BG group (p < 0.05). Meanwhile, BR treatment reduced the plasma levels of TNF-α, IL-1β, and IL-6, and increased the level of IL-10 (p < 0.05). Inflammatory cytokines are important factors that affect the recurrence of resected CP. Serum paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2 in BR had a strong negative relationship with the plasma levels of Ang PKB/Akt. **Conclusion.** BR significantly reduces the recurrence risk of resected CP by affecting Ang PKB/Akt signaling.

1. Introduction

A colonic polyp (CP) is a polyp growing on the surface of the colon, and untreated CP is the more likely precursor to develop colorectal cancer in most patients [1]. No effective drug has been proven or is recommended to treat CP yet. Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), notably aspirin, may reduce the rates of cancerous CP [2] and colon cancer [3] and rectal cancer [4]. However, the side effects of aspirin are also remarkable, such as rapid breathing and seizure; severe nausea, vomiting, and stomach pain; vomit and fever [5]. Therefore, it is necessary to explore natural products with few side effects for prevention of CP risk.

_Bupleuri Radix_ (BR) is a famous traditional Chinese herb and exhibits various biological activities such as anticancer, antimicrobial, and antiviral properties [6, 7]. Paeoniflorin, naringin, sennoside A, baicalin, baicalein, and saikosaponin A are the main components of BR [8] and have been reported to show inhibitory function on various cancers [9–11]. However, its function on CP development remains unclear. Angiogenesis will promote polyp growth and progression [12]. BR is one of main herbs having antiangiogenic effects [13]. Angiogenin-2-induced protein kinase B (Ang PKB)/Akt signaling is necessary for angiogenesis [14]. Thus, BR possibly inhibits CP progression via Ang PKB/Akt signaling. We aimed to explore the effects of BR on the recurrence of resected CP by investigating the
expression of Ang PKB/Akt and the relationship between serum main components of BR and plasma Ang PKB/Akt.

2. Materials and Methods

2.1. HPLC Analysis of BR Extracts. BR roots were purchased from Yantai Zhengsu Medical Technology Co., Ltd. (Yantai, Shandong, China). Dried and pulverized roots (10 g) of BR were extracted with 95% ethanol (1 L, 1 h), and the extracts were evaporated in vacuum to produce dark-brown residues. The residues were resuspended in 95% ethanol to a final volume of 10 mg/mL and filtered using a MF-Millipore membrane filter (0.45 μm pore size) and then directly applied to an Agilent 1200 series HPLC system (Santa Clara, CA, USA). The HPLC analysis was carried out with an Agilent TC-C18 column (250 mm × 4.6 mm, 5 μm), the mobile phase acetonitrile (A)-0.1% phosphoric acid aqueous solution (B), gradient elution (0–10 min, 5%–15% A; 10–50 min, 15%–42% A; 50–60 min, 42%–68% A), column temperature 30°C, flow rate 1.0 mL/min, detection wavelengths between 230 nm, and injection volume 10 μL. Meanwhile, paoniflorin (lot number: PRF9031342, purity: 98.91%), baicalin (lot number: PRF9091201, purity: 98.68%), saikosaponin A (lot number: PRF9022503, purity: 98.18%), and bupleurum saponin B2 (batch number: RF9062242, purity: 99.79%) were purchased from Chengdu Prefa Technology Development Co., Ltd. (Chengdu, China). All these standards were measured under the same HPLC condition.

2.2. Participants. This study was approved by the Ethics Committee of Yantai Hospital of Traditional Chinese Medicine and performed according to the Helsinki Declaration. All patients and controls provided their written informed consent. From March 3, 2017, to July 3, 2018, 298 patients had CP diameter > 10 mm and would receive endoscopic resection of CPs at Yantai Hospital of Traditional Chinese Medicine, and all data were analyzed by our authors.

2.3. Inclusion Criteria. The following inclusion criteria were used: (1) ≥40 years of age; (2) an endoscopic CP >10 mm in diameter; (3) complete medical records.

2.4. Exclusion Criteria. The following were the exclusion criteria: abnormal intestinal position due to congenital malformations or surgery; a thicker than normal abdominal wall; absence of polyps in patients; polyps being either unresected or observed, but not retrieved; patients who had a history of colectomy or proctectomy.

2.5. Sample Size Calculation. Sample size was calculated based on 95% confidence interval (α = 5%) and 80% power (β = 10%) and a sampling formula [15]: n = (2 × (Zα + Zβ)2 × SD2)/d2, where Zα = 1.96, Zβ = 1.28 [16]. The size of CP was the main variable of interest, 22.5 was the SD of CP size percent detected in the previous experiment, and 10% was postulated as a clinically significant difference in CP size between the two groups (d). Therefore, n = (2 × (1.96 + 1.28)2 × 22.52)/102 = 106.6. Considering 10% possibility of dropouts, n = 60 in each group were recruited.

2.6. Endoscopic Resection of CPs. CPs were resected by specially trained endoscopists using snare polypectomy or biopsy forceps. The method for endoscopic resection was chosen based on a surgery procedure. A circumferential incision was conducted using an electrosurgical knife (Spectronics, Westbury, NY, USA), and then submucosal dissection was performed. Medical results were recorded by two single reviewers. Doubts and discrepancies regarding surgery results were solved by the authors (MY and XW). The variables between the two groups were also investigated, such as gender, CP diagnosis, and the number of polyps and their size.

2.7. Patients Grouping. After surgery, 120 patients were recruited by two investigators according to inclusion and exclusion criteria and assigned to the aspirin group (80 mg aspirin orally administered at 8:00 AM each day) and the BR group (2 g BR orally administered at 8:00 AM each day) [17] using the random number generated by a computer. The intervention was not revealed, and each patient received his or her number using a letter envelope. All result data were analyzed by two statistic experts. The follow-up duration was one year, and the patients would be excluded from the present experiment if he or she wanted to give up the present intervention or severe side effects occurred and needed further treatment.

2.8. Inflammatory Analysis. Before the experiment, after one-month surgery and one-year surgery, 10 ml blood was obtained from each patient via venipuncture, and 3 ml blood was used for the measurement of plasma inflammatory cytokines. The levels of TNF-α (ab181421), IL-1β (ab46052), IL-6 (ab46027), and IL-10 (ab46034) in serum were assessed by using ELISA kits from Abcam (Chicago, IL USA) and an automatic blood chemical analyzer (Hitachi, Tokyo, Japan).

The pretreatment neutrophil-to-lymphocyte ratio (NLR) is an independent predictor of prognosis in increased risk of CPs [18]. Immunohistochemical staining for CPs was performed using formalin-fixed, paraffin-embedded CPs tissue sections (4 μm thick) according to a previous report. Sections were then dewaxed in xylene, stained in hematoxylin and eosin (H&E), dehydrated, and mounted with a coverslip [19]. NLR has been widely used as a predictive factor for inflammatory status [20–23] and analyzed in the present work.

2.9. Plasma Angiogenin-2 and PKB/Akt Concentrations. Two ml from the previously mentioned blood was used for the measurement of angiogenin-2 and PKB/Akt. Plasma angiogenin-2 (ab99970) and PKB/Akt (ab100662) were measured using the kits from Abcam (Cambridge, MA, USA).
2.10. Primary Outcomes. After one-month surgery, primary outcomes were measured, including polyp detection, polyp removal, diagnostic biopsy, and plasma levels of inflammatory cytokines, angiogenin-2, and PKB/Akt. Polyp detection was defined according to ICD-9-CM codes 211.3 and 211.4 on the colonoscopy claim [24]. According to the size classification of CP (≤5 mm, small; 6–9 mm, medium; ≥10 mm, large) [25], more generally, the CP ≥10 mm in diameter was resected [26]. Therefore, patients with large CP were included in the present study after the CP was accurately diagnosed with gastrointestinal endoscopy as Figure S1 shows [27].

2.11. Secondary Outcomes. After one-year follow-up, the secondary outcomes were measured, including the recurrence rate of resected CPs, side effects (rapid breathing, seizure; severe nausea, vomiting, and stomach pain; vomit and fever), and plasma levels of angiogenin-2 and PKB/Akt. Liver injury was examined by measuring the related biochemical indices from 5-mL serum, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), albumin (ALB), and globulin (G). All these parameters were measured by using the kits from Zhejiang EKN Biotechnology Co. Ltd (Wenzhou, China).

2.12. Statistical Analysis. All data were presented as mean values ± standard deviation (SD). The recurrence rate of resected CPs was evaluated using the Kaplan-Meier estimate along with the 95% confidence interval (CI). t-tests, analysis of variance (ANOVA), and chi-square tests were used to compare the variables. The test of Spearman correlation coefficients was used to explore the relationship between the levels of serum bupleurum saponins and plasma Ang PKB/Akt. All statistical analyses were performed by using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). p < 0.05 was considered statistically significant.

3. Results

3.1. The Main Components of BR. Comparing with the standards (Figure 1(a)), the main components of BR are paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2 (Figure 1(b)). HPLC analysis showed that there were no such compounds in the serum from the AG group (Figure 1(c)), and the main compounds of BR could be found in the serum from the BG group (Figure 1(d) and Table S1).

3.2. Baseline Characters. The complete polyp resection was achieved in all the polyps and marginal biopsies investigation demonstrated that no residual polyp tissue was found. After one-month surgery, no one withdrew from the present study. There were stable results and no significant side effects. After one-year follow-up, five patients were removed from the AG group because of significant side effects, and three patients were removed from the BG group because they could not take the medicine on time for more than five days. Thus, 55 and 57 patients finished the present study from the AG and BG groups (Figure 2), respectively. The number of changes would not affect the final statistical results. The statistical difference was insignificant for median age, gender distribution, the duration of CPs, polyp characteristics, CP histology, and resecting technique between the two groups (Table 1, p < 0.05).

The values of NLR in most samples were similar between the two groups and the statistical difference was insignificant (Figure S2, p > 0.05). The neoplastic polyps (tubular adenoma, tubulovillous adenoma, and adenocarcinoma) had higher inflammatory status than the nonneoplastic polyps (serrated and hyperplastic, Table 1) (Figure S2, p < 0.05).

3.3. Primary Outcomes. ELISA analysis showed that the statistical difference for the plasma levels of TNF-α (Figure 3(a)), IL-1β (Figure 3(b)), IL-6 (Figure 3(c)), and IL-10 (Figure 3(d)) was insignificant before surgery and after one-month surgery between the two groups (Figure 3, p > 0.05). Similarly, ELISA analysis showed that the statistical difference for the plasma levels of angiogenin-2 (Figure 4(a)) and PKB/Akt (Figure 4(b)) was insignificant before surgery and after one-month surgery between two groups (Figure 4, p > 0.05).

3.4. Secondary Outcomes. The normal side effects included rapid breathing and seizure; severe nausea, vomiting, and stomach pain; vomit and fever in both groups. The side effects (rapid breathing and seizure; severe nausea and stomach pain) in the AG group was higher than that in the BG group (Table 2, p < 0.05). The results suggest BR treatment had fewer side effects than aspirin treatment.

ELISA analysis showed that the statistical difference for the plasma levels of TNF-α (Figure 5(a)), IL-1β (Figure 5(b)), IL-6 (Figure 5(c)), and IL-10 (Figure 5(d)) was significant after one-year surgery between the two groups (Figure 5, p < 0.05). Meanwhile, the plasma levels of TNF-α (Figure 5(a)), IL-1β (Figure 5(b)), and IL-6 (Figure 5(c)) in the group with the recurrence of resected CP were higher than those in the group without recurrence, whereas the level of IL-10 (Figure 5(d)) in the group with the recurrence of resected CP was lower than that in the group without recurrence (Figure 5, p < 0.05). The results suggest that inflammatory cytokines are important factors to affect the recurrence of resected CP.

Similarly, ELISA analysis showed that the statistical difference for the plasma levels of angiogenin-2 (Figure 6(a)) and PKB/Akt (Figure 6(b)) was significant before surgery and after one-year surgery between the two groups (Figure 6, p < 0.05). The results suggest BR treatment reduced inflammatory responses and plasma levels of angiogenin-2 and PKB/Akt.

The recurrence of resected CPs was investigated at follow-up colonoscopy at the exact polyp site or in the colonic segment having index polypectomy. The recurrence rate of resected CPs in the AG group was higher than that in
the BG group (Table 3, \( p < 0.05 \)). The results suggest BR treatment reduced resected CP recurrence rate better than aspirin intervention.

3.5. Serum Paeoniflorin, Baicalin, Saikosaponin A, and Bupleurum Saponin B2 Had a Strong Negative Relationship with the Plasma Levels of Ang PKB/Akt. The tests of Spearman correlation coefficients showed that serum levels of paeoniflorin (Figure 7(a)), baicalin (Figure 7(b)), saikosaponin A (Figure 7(c)), and bupleurum saponin B2 (Figure 7(d)) were increasing with the reduction in the levels of plasma levels of Ang. Serum paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2 had a strong negative relationship with the plasma levels of Ang (\( p < 0.001 \)). Similarly, serum levels of paeoniflorin (Figure 7(e)), baicalin (Figure 7(f)), saikosaponin A (Figure 7(g)), and bupleurum saponin B2 (Figure 7(h)) were increasing with the reduction in the levels of plasma levels of PKB/Akt. Serum paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2 had a strong negative relationship with the plasma levels of PKB/Akt (\( p < 0.001 \)).

3.6. BR Treatment Did Not Cause Liver Injury according to Serum Biochemical Analysis. Serum biochemical analysis showed that all the parameters were similar between the two groups, including ALT, AST, ALP, GGT, TBIL, DBIL, TP, ALB, and G (Table 4, \( p > 0.05 \)). The results suggest that BR treatment will not cause liver injury according to serum biochemical analysis.

4. Discussion
CP is relatively easier to cure than colorectal cancer (CRC), but if not treated in time, colorectal polyps possibly develop into colorectal cancer [28]. CRC is the third most common cancer worldwide and the fourth most common cause of mortality [29]. Earlier detection of CP will improve survival rate of the patients [30]. Comparatively, it will take a long time and the cancerous rate of colonic polyp is low, and colorectal polyp is associated with greater morbidity than colonic polyp [31, 32].

In our cohort of patients, the effects of BR on the recurrence rate of resected CPs were explored. Overall, our study concluded that BR was effective and a safe therapy for
the patients with polyps > 10 mm undergoing CP resection. BR effectively prevented the recurrence rate of resected CPs by reducing the plasma levels of proinflammatory cytokines TNF-α (Figure 5(a)), IL-1β (Figure 5(b)), and IL-6 (Figure 5(c)) and increasing the level of anti-inflammatory cytokine IL-10 (Figure 5(d)). More importantly, BR significantly reduced the plasma levels of vascular angiogenic factors angiogenin-2 [33, 34] and PKB/Akt, which play

### Table 1: Baseline characters of two groups.

| Parameters | AG, n = 55 | BG, n = 57 | t or χ² values | p |
|------------|------------|------------|----------------|---|
| Median age, years (95% CI) | 49.1 (40.2–85.3) | 51.2 (42.4–88.6) | 0.654 | 0.279 |
| Median duration of disease, years (95% CI) | 6.3 (0.5–15.6) | 6.6 (0.5–12.9) | 0.563 | 0.426 |
| Gender, male cases (%) | 37 (67.3) | 40 (70.2) | 0.110 | 0.740 |
| Polyp characteristics | | | | |
| Median size of polyp, mm (95% CI) | 16.4 (11.2–26.1) | 15.1 (12.4–25.7) | 0.758 | 0.134 |
| Ascending colon | 20 (36.4) | 19 (33.3) | 0.827 | 0.935 |
| Transverse colon | 8 (14.5) | 10 (17.5) | | |
| Descending colon | 4 (7.3) | 6 (10.5) | | |
| Sigmoid colon | 13 (23.6) | 11 (19.3) | | |
| Rectum | 10 (18.2) | 11 (19.3) | | |
| Histology, n (%) | | | | |
| Tubular adenoma | 31 (56.4) | 32 (56.1) | 1.638 | 0.802 |
| Tubulovillous adenoma | 6 (10.9) | 5 (8.8) | | |
| Adenocarcinoma | 1 (1.8) | 3 (5.3) | | |
| Serrated | 11 (20) | 13 (22.8) | | |
| Hyperplastic | 6 (10.9) | 4 (7) | | |
| Resectioning technique, n (%) | | | | |
| En bloc | 37 (67.3) | 35 (61.4) | 0.420 | 0.517 |
| Piecemeal | 18 (32.7) | 22 (38.6) | | |

*t*-test for continuous data and Chi-square for count number. The statistical difference was significant if *p* < 0.05.
Figure 3: Plasma levels of inflammatory cytokines in primary outcomes after one-month surgery. (a) TNF-α. (b) IL-1β. (c) IL-6. (d) IL-10. n = 55 and 57 for AG and BG groups, respectively. * p < 0.05 vs. before surgery.

Figure 4: Plasma levels of angiogenic factors in primary outcomes after one-month surgery. (a) Angiogenin-2. (b) PKB/Akt. n = 55 and 57 for AG and BG groups, respectively.
important roles in the growth and progression of polyps, and colorectal carcinogenesis. The inflammatory cells play an important role in inflammatory infiltrate, and NLR values were analyzed in primary biopsies (Figure S2). However, the new biopsies were seldom found and the CP size was small, and the NLR data were not compared between the two groups after one-year treatment.

BR is a very popular herbal medicine in China, and its anti-inflammatory properties have been reported [35, 36]. Our results also showed the similar results by improving anti-inflammatory activities in the CP patients. Inflammatory cytokines are important factors to affect the recurrence of resected CP. The inhibitory function of BR on the level of PKB/Akt has been reported in human umbilical vein endothelial cells (HUVECs) [37]. However, the potential therapeutic effects of BR on various cancers have also been widely reported [38–42]. However, the effects of BR on polyps, especially CP, have seldom been reported. There was still no report for the effects of BR on the expression of angiogenin-2 before the present work although angiogenin-2

### Table 2: Side effects between the two groups.

| Side effects, n (%)       | AG, n = 55 | BG, n = 57 | χ² values | p     |
|---------------------------|------------|------------|-----------|-------|
| Rapid breathing           | 11 (20)    | 1 (1.8)    | 9.741     | 0.002 |
| Seizure                   | 6 (10.9)   | 4 (7.3)    | 0.153     | 0.696 |
| Severe nausea             | 12 (21.8)  | 2 (3.6)    | 8.579     | 0.003 |
| Vomiting                  | 13 (23.6)  | 10 (18.2)  | 0.637     | 0.425 |
| Stomach pain              | 18 (32.7)  | 3 (5.5)    | 13.859    | 0.000 |
| Vomit                     | 4 (7.3)    | 2 (3.6)    | 0.216     | 0.642 |
| Fever                     | 3 (5.5)    | 1 (1.8)    | 0.298     | 0.585 |

Chi-square for count number. The statistical difference was significant if \( p < 0.05 \).

**Figure 5**: Plasma levels of inflammatory cytokines in secondary outcomes after one-year follow-up. (a) TNF-α. (b) IL-1β. (c) IL-6. (d) IL-10. \( n = 55 \) and 57 for AG and BG groups, respectively. Symbols * and # stand for the significant difference between the two groups. * \( p < 0.05 \) vs. the recurrence of resected CP group and # \( p < 0.05 \) vs. the AG group.
**Figure 6:** Plasma levels of angiogenic factors in secondary outcomes after one-year follow-up. (a) Angiogenin-2. (b) PKB/Akt. n = 55 and 57 for AG and BG groups, respectively. Symbols * and # stand for the significant difference between the two groups. * p < 0.05 vs. the recurrence of resected CP group and # p < 0.05 vs. the AG group.

**Table 3:** Recurrence of CPs between the two groups, n (%).

| Types        | AG, n = 55 | BG, n = 57 | χ² values | p    |
|--------------|------------|------------|-----------|------|
| 1 recurrence | 11 (20)    | 6 (20)     | 4.597     | 0.032|
| 2 recurrences| 5 (9.1)    | 1 (9.1)    |           |      |
| 3 recurrences| 1 (1.8)    | 1 (1.8)    |           |      |

Chi-square for count number. The statistical difference was significant if p < 0.05.

**Figure 7:** Continued.
plays a crucial role in the progression and risk of polyps [43] and tumorigenesis [44–47]. Correlation test showed that the main ingredients paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2 had a strong negative relationship with the plasma levels of Ang PKB/Akt (Figure 7). Thus, BR may exert its function via these main compounds.

More importantly, BR has a few side effects as natural products and causes fewer side effects or little liver injury when compared with aspirin therapy (Tables 2 and 4). BR has been reported to reduce 6-hydroxydopamine- (6-OHDA-) induced cytotoxicity in vitro and in vivo [48]. BR is often used with clozapine in schizophrenia patients to reduce its side effects.
and improve therapeutic efficacy [49]. All these results suggest that BR is a potential drug for CP therapy with high safety.

5. Limitations
There were some limitations to the present study: all polyp diameters > 10 mm were included in the work, including both polypoid and flat. However, more than 30% of the polyps were nonpolypoid and therefore clinically very relevant. The recurrence of resected CPs in the larger polyps was significantly more than in the smaller ones, and they were also still endoscopically treatable. The follow-up and surveillance procedures performed were conducted at our hospital, which made the final data more meaningful. The experiments were performed by many different gastroenterologists, who had different techniques in the surgery. The present data showed the majority of gastroenterology practices. The long-term effects of BR on the recurrence of resected CPs are still needed to be explored in the future. The classification of colonic types is complex (Figure S3) and cannot be applied to our small population sample in this study. In the present work, the colonic polyps were schematically divided into two major polyp types, neoplastic polyps (tubular adenoma, tubulovillous adenoma, and adenocarcinoma) and non-neoplastic polyps (serrated and hyperplastic, Table 1). Serrated polyp is similar in morphology to the hyperplastic polyp, but the former has a malignant potential. Only a few types of colonic polyps were found with a small number in the present work. Statistical analysis cannot be performed for most colonic polyp types. These important issues should be addressed in a larger population sample in the future work.

6. Conclusion
In conclusion, the effects of BR on the recurrence of resected CP were explored here. We show that BR is a feasible and curative process, which may help reduce the recurrence of resected CP in CP patients who underwent CP by reducing the plasma levels of inflammatory cytokines and vascular angiogenic factors angiogenin-2 and PKB/Akt and increasing the level of anti-inflammatory cytokines. BR might be used as a potential drug in the prevention of the progression and risk of CPs via its main ingredients paeoniflorin, baicalin, saikosaponin A, and bupleurum saponin B2.

Data Availability
The data are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that there are no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors’ Contributions
OG, GY, and MY designed and performed the experiment. GY, MY, and XW analyzed all data. MY and XW wrote the paper. All authors agreed to the final submission. Qiang Gao and Guihong Yu contributed equally to this work.

Acknowledgments
The present study was supported by Yantai Science and Technology Project (2019YD048).

Supplementary Materials
Figure S1: colorectal polyps were diagnosed with gastrointestinal endoscopy. Figure S2: neutrophil-to-lymphocyte ratio (NLR) between two groups. n = 38 and 17 for neoplastic and nonneoplastic samples in the AG group, and n = 40 and 17 for neoplastic and nonneoplastic samples in the BG group. The statistical difference was significant if p < 0.05 vs. the neoplastic group. Figure S3: classification of colonic polyps. Table S1: the concentrations of Ang and PKB/Akt, and the serum levels of compounds from BR in the BG group. (Supplementary Materials)

References
[1] M. Mangifesta, L. Mancabelli, C. Milani et al., “Mucosal microbiota of intestinal polyps reveals putative biomarkers of colorectal cancer,” Scientific Reports, vol. 8, pp. 1–9, 2018.
[2] C. Fan, A. Younis, C. E. Bookhout, and S. D. Crockett, “Management of serrated polyps of the colon,” Current Treatment Options in Gastroenterology, vol. 16, no. 1, pp. 182–202, 2018.
[3] R. T. Gray, M. M. Cantwell, H. G. Coleman et al., “Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study,” Clinical and Translational Gastroenterology, vol. 8, no. 4, p. e91, 2017.
[4] K. J. Gash, A. C. Chambers, D. E. Cotton, A. C. Williams, and M. G. Thomas, “Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy,” British Journal of Cancer, vol. 117, no. 2, pp. 210–219, 2017.
[5] S. Ahmad, S. Ali, I. Alam, S. Alam, N. Alam, and M. Ali, “Drug interactions of OTC analgesics-aspirin: a review,” Research Journal of Pharmacy and Technology, vol. 8, no. 5, pp. 580–586, 2015.
[6] J. Wang, H. Qi, X. Zhang et al., “Saikosaponin D from radix bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling,” Biomedicine & Pharmacotherapy, vol. 108, pp. 724–733, 2018.
[7] S. Jia, W. Zhou, J. Wu et al., “A biomolecular network-based strategy deciphers the underlying molecular mechanisms of bupleuri radix/curcumae radix medicine pair in the treatment of hepatitis C,” European Journal of Integrative Medicine, vol. 33, p. 101043, 2020.
[8] C.-Y. Li, C.-H. Chiu, H.-S. Huang, C.-H. Lin, and T.-S. Wu, “High-performance liquid chromatographic method for simultaneous quantification of eight major biologically active ingredients in ‘Da-Chai-Hu-Tang’ Preparation,” Biomedical Chromatography, vol. 20, no. 4, pp. 305–308, 2006.
[9] H. Wu, W. Li, T. Wang, Y. Shu, and P. Liu, "Paeoniflorin suppress NF-kB activation through modulation of IκBα and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells," *Biomedicine & Pharmacotherapy*, vol. 62, no. 9, pp. 659–666, 2008.

[10] K. Franek, Z. Zhou, W. D. Zhang, and W. Chen, "In vitro studies of baicalin alone or in combination with *Salvia miltiorrhiza* extract as a potential anti-cancer agent," *International Journal of Oncology*, vol. 26, no. 1, pp. 217–224, 2005.

[11] S. J. Kang, Y. J. Lee, S. G. Kang et al., "Caspase-4 is essential for saikosaponin-a-induced apoptosis acting upstream of caspase-2 and γ-H2AX in colon cancer cells," *Oncotarget*, vol. 8, no. 59, pp. 100433–100448, 2017.

[12] E. Gounaris, C. H. Tung, C. Restaino et al., "Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth," *PloS One*, vol. 3, no. 8, p. e2916, 2008.

[13] X. Zhao, J. Liu, L. Feng et al., "Anti-angiogenic effects of Qingdu granule on breast cancer through inhibiting NFAT signaling pathway," *Journal of Ethnopharmacology*, vol. 222, pp. 261–269, 2018.

[14] H.-M. Kim, D.-K. Kang, H. Y. Kim, S. S. Kang, and S.-I. Chang, "Angiogenin-induced protein kinase B/Akt activation is necessary for angiogenesis but is independent of nuclear translocation of angiogenin in HUVE cells," *Biochemical and Biophysical Research Communications*, vol. 352, no. 2, pp. 509–513, 2007.

[15] J. P. Thakur, R. B. Rana, and A. Pokharel, "Ketamine with midazolam and ketamine alone as oral premedication in children," *Journal of Society of Anesthesiologists of Nepal*, vol. 4, no. 2, pp. 66–73, 2018.

[16] K. K. Gupta, J. P. Attrii, A. Singh, H. Kaur, and G. Kaur, "Basic concepts for sample size calculation: critical step for any clinical trials!" *Saudi Journal of Anaesthesia*, vol. 10, no. 3, p. 328, 2016.

[17] S.-J. Kang, E.-H. Jo, G.-J. Yang, H.-W. Shim, J.-E. Hong, and M.-C. Park, "Efficacy and safety of Soshiho-tang in patients with atopic dermatitis and gastrointestinal disorders: study protocol for a double-blind, randomized, and placebo-controlled clinical trial," *Medicine*, vol. 98, no. 18, p. e15479, 2019.

[18] J. H. Kim, K. I. Cho, Y. A. Kim, and S. J. Park, "Elevated neutrophil-to-lymphocyte ratio in metabolic syndrome is associated with increased risk of colorectal adenoma," *Metabolic Syndrome and Related Disorders*, vol. 15, no. 8, pp. 393–399, 2017.

[19] P. Ghanghas, S. Jain, C. Rana, and S. N. Sanyal, "Chemo-prevention of colon cancer through inhibition of angiogenesis and induction of apoptosis by nonsteroidal anti-inflammatory drugs," *Journal of Environmental Pathology, Toxicology and Oncology*, vol. 35, no. 3, pp. 273–289, 2016.

[20] C. Van Berckelaer, M. Van Geyt, S. Linders et al., "A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer," *The Breast*, vol. 53, pp. 212–220, 2020.

[21] M. Karatas, M. Buyuksekeri, M. Gunduzoz, G. Ozakinci, and T. N. Ozis, "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as inflammatory markers in patients with Welders' lung disease," *Journal of Occupational & Environmental Medicine*, vol. 62, pp. e523–e526, 2020.

[22] G. Bora Makal and O. Yildirim, "Are the C-reactive protein/albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (NLR) novel inflammatory biomarkers in the early diagnosis of postoperative complications after laparoscopic sleeve gastrectomy?" *Obesity Research & Clinical Practice*, vol. 14, no. 5, pp. 467–472, 2020.

[23] Q. Li, P. Chen, S. Shi et al., "Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator of poor prognosis in IgA nephropathy," *International Immunopharmacology*, vol. 87, p. 106811, 2020.

[24] C. W. Ko, J. A. Dominitz, P. Green, W. Kreuter, and L.-M. Baldwin, "Specially differences in polyp detection, removal, and biopsy during colonoscopy," *The American Journal of Medicine*, vol. 123, no. 6, pp. 528–535, 2010.

[25] S. Gupta, B. A. Balasubramanian, T. Fu, R. M. Genta, D. C. Rockey, and R. Lash, "Polyps with advanced neoplasia are smaller in the right than in the left colon: implications for colorectal cancer screening," *Clinical Gastroenterology and Hepatology*, vol. 10, no. 12, pp. 1395–1401, 2012.

[26] K. Siau, S. Ishaq, S. Cadoni, T. Kuwai, A. Yusuuf, and N. Suzuki, "Feasibility and outcomes of underwater endoscopic mucosal resection for ≥10 mm colorectal polyps," *Surgical Endoscopy*, vol. 32, no. 6, pp. 2656–2663, 2018.

[27] N. Yoshida, Y. Naito, Y. Inada et al., "The detection of surface patterns by flexible spectral imaging color enhancement without magnification for diagnosis of colorectal polyps," *International Journal of Colorectal Disease*, vol. 27, no. 5, pp. 605–611, 2012.

[28] Q. Li, G. Yang, Z. Chen et al., "Colorectal polyp segmentation using a fully convolutional neural network," in *Proceedings of 2017 10th International Congress on Image and Signal Processing, BioMedical and Engineering Informatics (CISP-BMEI)*, vol. 1–5, IEEE, Shanghai, China, October 2017.

[29] M. Araghi, I. Soerjomataram, M. Jenkins et al., "Global trends in colorectal cancer mortality: projections to the year 2035," *International Journal of Cancer*, vol. 144, no. 12, pp. 2992–3000, 2019.

[30] S. Qiu, S. Nikolau, F. Fiorentino et al., "Exploratory analysis of plasma neutrophilin as a novel biomarker for early detection of colorectal polyp and cancer," *Hormones and Cancer*, vol. 10, no. 2-3, pp. 128–135, 2019.

[31] Y. Guo, S. Zong, Y. Pu, B. Xu, T. Zhang, and B. Wang, "Advances in pharmaceutical strategies enhancing the efficiencies of oral colon-targeted delivery systems in inflammatory bowel disease," *Molecules*, vol. 23, no. 7, p. 1622, 2018.

[32] D. K. Rex, A. Shaukat, and M. B. Wallace, "Optimal management of malignant polyps, from endoscopic assessment and resection to decisions about surgery," *Clinical Gastroenterology and Hepatology*, vol. 17, no. 8, pp. 1428–1437, 2019.

[33] J.-M. Rong, H.-Z. Ji, X.-W. Wu et al., "Increased expression of chymase in inflammatory polyps in elderly patients with functional bowel disorder," *Experimental and Therapeutic Medicine*, vol. 7, no. 2, pp. 371–374, 2014.

[34] L. W. Slice, T. Chiu, and E. Rozengurt, "Angiotensin II and L.-M. Baldwin, "Clinical significance of redox effects of kampo formulae, a traditional Japanese herbal medicine: comprehensive estimation of multiple antioxidative activities," *Pharmacology*, vol. 10, p. 623, 2019.

[35] M. Araghi, I. Soerjomataram, M. Jenkins et al., "Global trends in colorectal cancer mortality: projections to the year 2035," *International Journal of Cancer*, vol. 144, no. 12, pp. 2992–3000, 2019.

[36] S. Qiu, S. Nikolau, F. Fiorentino et al., "Exploratory analysis of plasma neutrophilin as a novel biomarker for early detection of colorectal polyp and cancer," *Hormones and Cancer*, vol. 10, no. 2-3, pp. 128–135, 2019.
[37] K.-G. Shyu, S.-C. Tsai, B.-W. Wang, Y.-C. Liu, and C.-C. Lee, “Saikosaponin C induces endothelial cells growth, migration and capillary tube formation,” *Life Sciences*, vol. 76, no. 7, pp. 813–826, 2004.

[38] Y. Wang, L. Zhao, X. Han et al., “Saikosaponin a inhibits triple-negative breast cancer growth and metastasis through downregulation of CXCR4,” *Frontiers in Oncology*, vol. 9, p. 1487, 2019.

[39] C. Y. Zhang, Z. M. Jiang, X.-F. Ma et al., “Saikosaponin-d inhibits the hepatoma cells and enhances chemosensitivity through SENP5-dependent inhibition of Gli1 SUMOylation under hypoxia,” *Frontiers in Pharmacology*, vol. 10, p. 1039, 2019.

[40] Z. X. Lin, J. F. Chen, and Y. Guo, “Analysis on traditional Chinese medicine prescriptions treating cancerous fever based on grey screening method combined with multivariate analysis method and discovery of new prescriptions,” *Zhongguo Zhong Yao Za Zhi*, vol. 44, pp. 2849–2857, 2019.

[41] Q. Ma, F. F Gao, X. He et al., “Antitumor effects of saikosaponin b2 on breast cancer cell proliferation and migration,” *Molecular Medicine Reports*, vol. 20, no. 2, pp. 1943–1951, 2019.

[42] X. Zhao, J. Liu, S. Ge et al., “Saikosaponin a inhibits breast cancer by regulating Th1/Th2 balance,” *Frontiers in Pharmacology*, vol. 10, p. 624, 2019.

[43] K. S. Hwang, I.-H. Park, H. Choi, S. H. Lee, S. H. Lee, and H.-M. Lee, “Increased expression of angiogenin in nasal polyps,” *American Journal of Rhinology & Allergy*, vol. 25, no. 1, pp. e23–e26, 2011.

[44] S. Li, K. A. Goncalves, B. Lyu, L. Yuan, and G. F. Hu, “Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitors,” *Communications Biology*, vol. 3, p. 26, 2020.

[45] S. Li, X. Shi, M. Chen et al., “Angiogenin promotes colorectal cancer metastasis via tiRNA production,” *International Journal of Cancer*, vol. 145, no. 5, pp. 1395–1407, 2019.

[46] A. Bruno, B. Bassani, D. G. D’Urso et al., “Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer,” *The FASEB Journal*, vol. 32, no. 10, pp. 5365–5377, 2018.

[47] Y.-N. Wang, H.-H. Lee, C.-K. Chou et al., “Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for Erlotinib sensitivity in pancreatic cancer,” *Cancer Cell*, vol. 33, no. 4, pp. 752–769, 2018.

[48] H. Eo, Y. Kwon, E. Huh et al., “Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinson’s disease,” *Biomedicine & Pharmacotherapy*, vol. 117, p. 109184, 2019.

[49] D. D. Tian, W. Wang, H. N. Wang, S. C. Sze, and Z. J. Zhang, “Pharmacokinetic evaluation of clozapine in concomitant sse of *Radix rehmanniae*, *Fructus Schisandrae*, *Radix Bupleuri*, or *Fructus Gardeniae* in rats,” *Molecules*, vol. 21, 2016.